Global Insulin Pen Market by Product Type, By Distribution Channel, By Application, By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26
|出版商||Blueweave Consulting & Research Private Limited||商品編碼||948285|
|出版日期||內容資訊||英文 186 Pages
|胰島素筆針型注射器的全球市場:各產品類型 、各流通管道，各用途，各地區的趨勢分析，市場佔有率，預測:2016年-2026年 Global Insulin Pen Market by Product Type, By Distribution Channel, By Application, By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26|
|出版日期: 2020年04月01日||內容資訊: 英文 186 Pages||
Global Insulin Pen Market by Product Type (Disposable, Reusable), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, diabetes Clinics), By Application (Type 1 Diabetes, Type 2 Diabetes), By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Trend Analysis, Competitive Market Share & Forecast, 2016-26.
The Global Insulin Pen Market valued USD 4300 million in 2019, and projected to reach USD 7800 million by 2026, at a CAGR of 8.8% during the forecast period 2020-2026. Insulin is necessary for the management of type 1 diabetes and is more commonly used for the medication of type 2 diabetes. The insulin pen was first launched over 20 years ago and has evolved to provide significant working advantages compared with the syringe and vial. Insulin Pen devices are now used by patients with diabetes globally, but there are marked geographic differences in the use of reusable and disposable pens. In many countries, syringe and vial are still the most popular method of delivering insulin, whereas, in many countries, the use of reusable or disposable pens is more common. Diabetes is an endocrine health problem that causes high levels of sugar in the blood. For diabetic patients, blood sugar must be monitored carefully using a glucometer. If insulin is necessary to be injected in order to regulate the activity of the pancreas, this can be accomplished using insulin injection pens, either pre-filled disposable or refillable. This allows for light and easy use while providing accurate information on the dose. These factors are expected to propel the insulin pen market growth during the forecast period.
An electronic insulin pen was designed for diabetic patient's dependent on insulin use in order to prevent wrong timing and wrong dosage caused by old age, vision, or mental illness. The insulin pen can be used electronically for routine dose injections and was designed to be able to used manually in the emergency. It is aimed that the patient can set the dose easily by using the fairly simple menu of the device. Additionally, the device was not designed as disposable, and the device was designed as reusable by changing the insulin tube. Because the tube chamber was designed to be suitable for all types of insulin, it can be used by changing the tube without using a different pen. Dose accuracy was adjusted with a low error by performing insulin dose measurements on a sensitive balance.
Diabetes is a metabolic disorder in both the developed and developing countries. It is expected that about 371 million people have disease worldwide and this number has been estimated to rise up to 552 million by 2030. The rate of prevalence of diabetes is high in Asian countries. About 92.3 and 63 million people in China and India suffer from this metabolic disorder respectively. Diabetes (T2D) reduces the life expectancy by 5-10 years. Prevalence of diabetes is rapidly increasing worldwide due to interactions between environmental factors, genetic factors and lifestyle. Furthermore, factors such as population growth, urbanization, aging, and increasing prevalence of obesity and physical inactivity are significantly contributing to the increasing global burden of diabetics. This is the major growth driver for the global insulin pen market.
The insulin pen offers better convenience, flexibility, and quality of life results with pen devices as compared to the conventional insulin delivery devices.6 Dose accuracy with insulin pens was also reported to be better in many studies in comparison to vials and syringes method, especially at low doses (≤5 IU). All these factors are essential in improving patient adherence to the treatment and also reducing hypoglycemic episodes.
With individual use of the pen device, the prospect of infection is decreased. Examples of such reusable insulin pens are Humapen® (for both human and analog insulins), NovoPen® 3 (for both human and analog insulins), Autopen® pen, Optipen®, and Wosulin pen. HumaPen® MEMOIR(TM) comes with a memory allowing diabetes patients, especially those on multiple mealtime doses, to record and examine their last 16 insulin doses. Insulin pens have shown dose accuracy before and after simulation of 5 years of use across a broad range of temperature and humidity conditions and after mechanical challenges.
North America expected to witness significant growth in the market during the forecast period
Insulin medication is deemed to be the center for the treatment of people who have diabetes, and in the United States, the adoption of insulin pens is increasing significantly as compared to the needles and syringes during the forecast period.
Asia-Pacific is also estimated to grow at a high CAGR during the forecast period due to the high population in China, India, and other Asian countries.